vs

Side-by-side financial comparison of MEDIFAST INC (MED) and TELOS CORP (TLS). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $46.8M, roughly 1.6× TELOS CORP). On growth, TELOS CORP posted the faster year-over-year revenue change (77.4% vs -36.9%). TELOS CORP produced more free cash flow last quarter ($8.0M vs $-6.6M). Over the past eight quarters, TELOS CORP's revenue compounded faster (25.7% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Telos Corporation is an information technology and cybersecurity company located in Ashburn, Virginia. Telos primarily serves government and enterprise clients, receiving a large number of its contracts from the United States Department of Defense. Customers are primarily military, intelligence and civilian agencies of the US government and NATO allies.

MED vs TLS — Head-to-Head

Bigger by revenue
MED
MED
1.6× larger
MED
$75.1M
$46.8M
TLS
Growing faster (revenue YoY)
TLS
TLS
+114.3% gap
TLS
77.4%
-36.9%
MED
More free cash flow
TLS
TLS
$14.6M more FCF
TLS
$8.0M
$-6.6M
MED
Faster 2-yr revenue CAGR
TLS
TLS
Annualised
TLS
25.7%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
TLS
TLS
Revenue
$75.1M
$46.8M
Net Profit
$-16.3M
Gross Margin
69.4%
35.0%
Operating Margin
-10.4%
-39.6%
Net Margin
-34.9%
Revenue YoY
-36.9%
77.4%
Net Profit YoY
-74.8%
EPS (diluted)
$-1.64
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
TLS
TLS
Q4 25
$75.1M
$46.8M
Q3 25
$89.4M
$51.4M
Q2 25
$105.6M
$36.0M
Q1 25
$115.7M
$30.6M
Q4 24
$119.0M
$26.4M
Q3 24
$140.2M
$23.8M
Q2 24
$168.6M
$28.5M
Q1 24
$174.7M
$29.6M
Net Profit
MED
MED
TLS
TLS
Q4 25
$-16.3M
Q3 25
$-2.3M
$-2.1M
Q2 25
$2.5M
$-9.5M
Q1 25
$-772.0K
$-8.6M
Q4 24
$-9.3M
Q3 24
$1.1M
$-28.1M
Q2 24
$-8.2M
$-7.8M
Q1 24
$8.3M
$-7.4M
Gross Margin
MED
MED
TLS
TLS
Q4 25
69.4%
35.0%
Q3 25
69.5%
39.9%
Q2 25
72.6%
33.2%
Q1 25
72.8%
39.8%
Q4 24
74.1%
40.3%
Q3 24
75.4%
13.2%
Q2 24
73.2%
34.1%
Q1 24
72.8%
37.0%
Operating Margin
MED
MED
TLS
TLS
Q4 25
-10.4%
-39.6%
Q3 25
-4.6%
-4.8%
Q2 25
-1.0%
-27.5%
Q1 25
-1.1%
-29.5%
Q4 24
0.6%
-37.6%
Q3 24
1.5%
-121.4%
Q2 24
-4.7%
-30.3%
Q1 24
4.5%
-28.5%
Net Margin
MED
MED
TLS
TLS
Q4 25
-34.9%
Q3 25
-2.5%
-4.1%
Q2 25
2.3%
-26.5%
Q1 25
-0.7%
-28.1%
Q4 24
-35.4%
Q3 24
0.8%
-118.0%
Q2 24
-4.8%
-27.2%
Q1 24
4.8%
-24.9%
EPS (diluted)
MED
MED
TLS
TLS
Q4 25
$-1.64
$-0.22
Q3 25
$-0.21
$-0.03
Q2 25
$0.22
$-0.13
Q1 25
$-0.07
$-0.12
Q4 24
$0.08
$-0.13
Q3 24
$0.10
$-0.39
Q2 24
$-0.75
$-0.11
Q1 24
$0.76
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
TLS
TLS
Cash + ST InvestmentsLiquidity on hand
$167.3M
$53.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$96.0M
Total Assets
$248.0M
$139.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
TLS
TLS
Q4 25
$167.3M
$53.2M
Q3 25
$173.5M
$59.0M
Q2 25
$162.7M
$57.0M
Q1 25
$164.6M
$57.8M
Q4 24
$162.3M
$54.6M
Q3 24
$170.0M
$69.8M
Q2 24
$163.5M
$80.1M
Q1 24
$156.4M
$93.9M
Stockholders' Equity
MED
MED
TLS
TLS
Q4 25
$198.9M
$96.0M
Q3 25
$214.7M
$119.7M
Q2 25
$216.0M
$118.4M
Q1 25
$211.0M
$126.1M
Q4 24
$210.1M
$127.1M
Q3 24
$207.3M
$129.5M
Q2 24
$205.3M
$149.1M
Q1 24
$211.0M
$154.4M
Total Assets
MED
MED
TLS
TLS
Q4 25
$248.0M
$139.9M
Q3 25
$268.2M
$164.3M
Q2 25
$269.3M
$165.0M
Q1 25
$280.0M
$158.1M
Q4 24
$284.2M
$158.2M
Q3 24
$291.2M
$166.3M
Q2 24
$293.5M
$182.4M
Q1 24
$302.8M
$195.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
TLS
TLS
Operating Cash FlowLast quarter
$-5.3M
$8.0M
Free Cash FlowOCF − Capex
$-6.6M
$8.0M
FCF MarginFCF / Revenue
-8.8%
17.0%
Capex IntensityCapex / Revenue
1.8%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$29.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
TLS
TLS
Q4 25
$-5.3M
$8.0M
Q3 25
$12.1M
$9.1M
Q2 25
$-3.4M
$7.0M
Q1 25
$3.4M
$6.1M
Q4 24
$-4.9M
$-10.5M
Q3 24
$9.1M
$-7.1M
Q2 24
$13.1M
$-8.0M
Q1 24
$7.3M
$-350.0K
Free Cash Flow
MED
MED
TLS
TLS
Q4 25
$-6.6M
$8.0M
Q3 25
$10.8M
$8.7M
Q2 25
$-4.8M
$6.8M
Q1 25
$1.9M
$6.0M
Q4 24
$-7.2M
$-12.4M
Q3 24
$7.7M
$-7.1M
Q2 24
$11.1M
$-8.2M
Q1 24
$5.4M
$-447.0K
FCF Margin
MED
MED
TLS
TLS
Q4 25
-8.8%
17.0%
Q3 25
12.0%
16.9%
Q2 25
-4.5%
19.0%
Q1 25
1.6%
19.5%
Q4 24
-6.1%
-47.0%
Q3 24
5.5%
-30.0%
Q2 24
6.6%
-28.9%
Q1 24
3.1%
-1.5%
Capex Intensity
MED
MED
TLS
TLS
Q4 25
1.8%
0.1%
Q3 25
1.5%
0.9%
Q2 25
1.3%
0.4%
Q1 25
1.3%
0.4%
Q4 24
1.9%
7.1%
Q3 24
1.0%
0.2%
Q2 24
1.1%
0.8%
Q1 24
1.1%
0.3%
Cash Conversion
MED
MED
TLS
TLS
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

TLS
TLS

Security Solutions Segment$44.8M96%
Secure Networks Segment$1.9M4%

Related Comparisons